TY - JOUR
T1 - Plasma levels of amyloid beta and other proinflammatory mediators in patients with age-related macular degeneration
AU - Guymer, Robyn
AU - Cipriani, Tania
AU - Rittenhouse, Kay D.
AU - Lim, Lyndell
AU - Robman, Liubov D.
AU - Li, Wenlin
AU - Wang, Wenlian
AU - Deng, Shibing
AU - Banerjee, Poulabi
PY - 2015/8
Y1 - 2015/8
N2 - Purpose: To investigate the plasma levels of amyloid beta (Aβ) and select inflammatory mediators in patients with various stages of AMD compared to that of age-matched controls, and discern a relationship to disease severity. Methods: Plasma samples were obtained from AMD subjects at various stages of disease—early (drusen only), geographic atrophy (GA), neovascular AMD (CNV)—and from controls of similar age without AMD. Samples were analyzed using a commercially available ELISA kit (sixteen cytokines) or LC/MS/MS (Aβ isotypes). Descriptive statistics were compiled on all analytes. Analysis of covariance (ANCOVA) was conducted to compare each analyte across AMD groups while adjusting for sex and age of the patients, and in comparison to the control group. Receiver operating characteristics plots were generated for the strongest predictor variables. Results: Levels of alternative spliced CC3 proteins were significantly different between controls and CNV groups (p < 0.05), with median levels almost twice higher in CNV than in controls. There was an increasing trend for plasma levels of Αβ isotypes across AMD progressive stages (p values ranged from 0.052 to 0.0012) (ANCOVA). When adjusted for multiple comparisons analysis, plasma Aβ 1–42 levels, and its ratio with Aβ 1–40 were the most significantly associated with late AMD stages. Consistently with the ANCOVA results for Αβ isotypes, the ROC curve showed a moderate prediction (AUC = - ~ 0.78) of AMD vs control using the Aβ 1−42 isotype. Conclusion: Plasma Aβ 1–42 may have utility as a systemic biomarker for AMD.
AB - Purpose: To investigate the plasma levels of amyloid beta (Aβ) and select inflammatory mediators in patients with various stages of AMD compared to that of age-matched controls, and discern a relationship to disease severity. Methods: Plasma samples were obtained from AMD subjects at various stages of disease—early (drusen only), geographic atrophy (GA), neovascular AMD (CNV)—and from controls of similar age without AMD. Samples were analyzed using a commercially available ELISA kit (sixteen cytokines) or LC/MS/MS (Aβ isotypes). Descriptive statistics were compiled on all analytes. Analysis of covariance (ANCOVA) was conducted to compare each analyte across AMD groups while adjusting for sex and age of the patients, and in comparison to the control group. Receiver operating characteristics plots were generated for the strongest predictor variables. Results: Levels of alternative spliced CC3 proteins were significantly different between controls and CNV groups (p < 0.05), with median levels almost twice higher in CNV than in controls. There was an increasing trend for plasma levels of Αβ isotypes across AMD progressive stages (p values ranged from 0.052 to 0.0012) (ANCOVA). When adjusted for multiple comparisons analysis, plasma Aβ 1–42 levels, and its ratio with Aβ 1–40 were the most significantly associated with late AMD stages. Consistently with the ANCOVA results for Αβ isotypes, the ROC curve showed a moderate prediction (AUC = - ~ 0.78) of AMD vs control using the Aβ 1−42 isotype. Conclusion: Plasma Aβ 1–42 may have utility as a systemic biomarker for AMD.
KW - Age-related macular degeneration (AMD)
KW - Amyloid beta
KW - Inflammatory mediators
UR - http://www.scopus.com/inward/record.url?scp=84938417001&partnerID=8YFLogxK
U2 - 10.1007/s00417-015-2970-x
DO - 10.1007/s00417-015-2970-x
M3 - Article
C2 - 25744331
AN - SCOPUS:84938417001
SN - 0721-832X
VL - 253
SP - 1347
EP - 1354
JO - Graefes Archive for Clinical and Experimental Ophthalmology
JF - Graefes Archive for Clinical and Experimental Ophthalmology
IS - 8
ER -